Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-GASTRIC05 first-line HER2-positive gastric/GEJ cancer trial
CTR20250981Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan, trastuzumab, pembrolizumab, capecitabine, fluorouracil in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Daiichi Sankyo Co., Ltd.. Started May 2025; status: active.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20250981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250981.